Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:ADMS
Date4/2014
Raised$48M
Post IPO Valuation

General Information

Websiteadamaspharma.com
CategoryBioTech
Phone510-450-3500
Emailinfo@adamaspharma...
Employees
Founded2000

Offices

Emeryville, USA
1900 Powell Street
Suite 1050
Emeryville, CA, 94608
USA

People

Chief Executive Officer & Chairman
Chief Financial Officer & SVP Corporate Development
SVP of Product Development
VP, Clinical Research
VP of Clinical Pharmacology
VP of Quality Assurance
VP of Regulatory
Board Member
Show All People

Acquisitions

Future Domain, 7/1996

Funding

TOTAL $82M
FUNDING TOTAL $82M
Series B, 5/2005
Mohr Davidow Ventures
$21M
Series C, 8/2007
$13M
Series C, 7/2008
$8M
Series D, 10/2009
Aeris Capital
DAG Ventures
Mohr Davidow Ventures
Northgate Capital
$40M

Tags

Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.

Recent Milestones

Videos

Screenshots

Stock Price

Sources

  1. Citation Needed [add]
  2. SEC D (sec.gov) [edit]
  3. SEC D (sec.gov) [edit]
  4. SEC D/A (sec.gov) [edit]
  5. Adamas Pharmaceuticals, Inc.: Series D $40M (onbiovc.com) [edit]
  6. Adamas Pharmaceuticals Estimates IPO to Price at $16-$18 A Share (pevc.dowjones.com) [edit]
Edit This Page
Last Edited 4/10/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy